

Set Name Query side by side		Hit Count Set Name result set		
DB=U				
<u>L7</u>	('LFA-3' or LFA3TIP or LFA3\$) and (treat\$ or therap\$ or prevent\$ or inhibit\$ or suppress\$)same (skin or dermatitis or psoriasis)	120	<u>L7</u>	
DB=USPT,PGPB,JPAB,EPAB,DWPI; PLUR=YES; OP=ADJ				
<u>L6</u>	('LFA-3' or LFA3TIP or LFA3\$) and (treat\$ or therap\$ or prevent\$ or inhibit\$ or suppress\$)same (skin or dermatitis or psoriasis)	181	<u>L6</u>	
DB=USPT,PGPB; PLUR=YES; OP=ADJ				
<u>L5</u>	('LFA-3' or LFA3TIP or LFA3\$) and (skin or dermatitis or psoriasis)	260	<u>L5</u>	
<u>L4</u>	('LFA-3' or LFA3TIP or LFA3\$)same (skin or dermatitis or psoriasis)	12	<u>L4</u>	
<u>L3</u>	('LFA-3' or LFA3TIP or LFA3\$) and (psoriasis)	89	<u>L3</u>	
<u>L2</u>	L1 and Ifa\$	10	<u>L2</u>	
<u>L1</u>	wallner-barbara\$	21	<u>L1</u>	

END OF SEARCH HISTORY





DATE: Saturday, March 29, 2003 Printable Copy Create Case

Generate Collection Print

Search Results - Record(s) 1 through 10 of 10 returned

bear of results record(s) I allough 10 of 10 fetalited.
1. 20020009449_05 Dec 00. 24 Jan 02. Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction. Wallner, Barbara P., et al. 424/154.1; A61K039/395.
□ 2. 6162432. 06 Jun 95; 19 Dec 00. Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction. Wallner: Barbara P., et al. 424/154.1; 424/130.1 424/133.1 424/134.1 424/135.1 424/141.1 424/143.1 424/144.1 424/152.1 424/175.1 424/175.1 424/175.1 514/15 514/8 514/863 514/888. A61K039/395 A61K035/26 A61K038/17.
3. <u>5928643</u> . 02 Jun 95; 27 Jul 99. Method of using CD2-binding domain of lymphocyte function associated antigen 3 to initiate T cell activation. <u>Wallner; Barbara P.</u> , et al. 424/134.1; 424/153.1 424/173.1 424/182.1 424/185.1 424/192.1 435/69.7 514/12 530/324 530/387.1. A61K039/395 A61K038/16 C12N015/62 C07K014/705.
4. 5914111. 02 Jun 95; 22 Jun 99. CD2-binding domain of lymphocyte function associated antigen-3. Wallner; Barbara P., et al. 424/134.1; 424/153.1 424/173.1 424/182.1 424/185.1 424/192.1 435/69.7 514/12 530/324 530/387.1. A61K039/395 A61K038/16 C12N015/62 C07K014/705.
5. 5728677. 02 Jun 95; 17 Mar 98. Methods of inhibiting T-cell dependent proliferation of peripheral blood lymphocytes using the CD2-binding domain of lymphocyte function associated antigen 3. Wallner; Barbara P., et al. 514/12; 424/185.1 424/809 514/13 514/15 530/868. A61K038/17 C07K014/705.
☐ 6. <u>5547853</u> . 21 Oct 92; 20 Aug 96. CD2-binding domain of lymphocyte function associated antigen 3. <u>Wallner; Barbara P.</u> , et al. 435/69.1; 435/252.3 435/320.1 435/69.7 435/810 436/86 514/2 530/350 536/23.4 536/23.5. C07K014/705 C12N015/12 C12N015/62.
7. 5354665. 13 Oct 92; 11 Oct 94. Recombinant DNA processes for producing PI-linked lymphocyte function associated antigen-3. Wallner, Barbara P., et al. 435/69.3; 514/2 514/8 530/350 530/387.1 530/395. C07K013/00 A61K037/02 C12N015/10.
□ 8. <u>5223394</u> . 10 Apr 89; 29 Jun 93. Recombinant DNA molecule comprising lymphocyte function-associated antigen 3 phosphatidylinositol linkage signal sequence. <u>Wallner; Barbara P.</u> . 435/6; 435/252.3 435/320.1 536/23.5 536/23.53. C12Q001/68 C12N015/00.
9. <u>5185441</u> . 26 Aug 88; 09 Feb 93. DNA sequences, recombinant DNA molecules and processes for producing PI-linked lymphocyte function associated antigen-3. <u>Wallner; Barbara P.</u> , et al. 435/356; 435/252.31 435/252.34 435/320.1 435/362 435/6 435/69.3 435/90 436/501 536/23.5. C07H021/00 C07H021/04 C12Q001/68.
□ 10. 4956281. 03 Jun 87; 11 Sep 90. DNA sequences, recombinant DNA molecules and processes for producing lymphocyte function associated antigen-3. Wallner, Barbara P., et al. 435/69.3; 435/252.31 435/252.33 435/252.34 435/252.35 435/254.11 435/254.22 435/320.1 435/356 435/366 536/23.1 536/23.5. C12P021/00 C12N015/00 C12N001/20.

Generate Collection | Print

Term	Documents
LFA\$	0
LFA.USPT,PGPB.	1751
LFAA.USPT,PGPB.	18
LFAAFPSFAG.USPT,PGPB.	1
LFAAISTRQY.USPT,PGPB.	1
LFAAS.USPT,PGPB.	5
LFAA1Z01618H.USPT,PGPB.	1
LFAA1200110H.USPT,PGPB.	1
LFAA12034.USPT,PGPB.	1
LFAA/MFAA.USPT,PGPB.	4
LFAB.USPT,PGPB.	2
(L1 AND LFA\$).USPT,PGPB.	10


There are more results than shown above. Click here to view the entire set.

Previous Page Next Page


2 of 2 3/29/03 10:07 AM

Set Name Query side by side		Hit Count	Set Name result set	
DB=DWPI; PLUR=YES; OP=ADJ				
<u>L5</u>	(puva or uv or chemotherapy) same (combination or combined)same psoriasis	42	<u>L5</u>	
DB=USPT; PLUR=YES; OP=ADJ				
<u>L4</u>	(uv or chemotherapy) same (combination or combined)same psoriasis	80	<u>L4</u>	
<u>L3</u>	(uv or chemotherapy) same (combination or combined)and psoriasis	829	<u>L3</u>	
<u>L2</u>	L1 and psoriasis	47	<u>L2</u>	
<u>L1</u>	(puva) same (combination or combined)	51	<u>L1</u>	

END OF SEARCH HISTORY



There are more results than shown above. Click here to view the entire set.



DATE: Saturday, March 29, 2003 Printable Copy Create Case

OR COMBINED)SAME PSORIASIS).DWPI.

Generate Collection

L4: Entry 72 of 80

File: USPT

Apr 1, 1986

DOCUMENT-IDENTIFIER: US 4579844 A TITLE: Topical anti-inflammatory drug therapy

Brief Summary Text (7):

We have discovered in the course of investigations with experimentally induced inflammation that topical treatment with a combination of certain steroidal and non-steroidal anti-inflammatory drugs results in unexpectedly improved suppression of inflammation than occurs when either drug is used alone. That is, either the combination is effective where the drugs used separately are not, or the combination provides more rapid, dramatic improvement than either drug alone, or the combination is equally effective at lower concentrations than either drug alone. This effect is postulated to result from the two drugs acting upon different aspects of the inflammatory response. Particularly in the case of UV-induced erythema, significant therapeutic effects (amelioration of the condition) are produced by combinations of the two types of drugs at concentration levels at which either drug alone has low or minimal effect. The steroid/non-steroid drug combination treatment of the present invention can also be used in the therapeutic treatment of a wide variety of dermatological disorders in which inflammation is a component. Examples of these diseases are psoriasis, eczema, contact dermatitis, atopic dermatitis, etc. Inflammation accompanying thermal or chemical burns as well as sunburn are other areas for application of the combination therapy of this invention, as are diaper rash, insect bite inflammation, gingival inflammation and pruritus. Also, vesicular diseases, especially those characterized by acantholysis, and other blistering conditions, appear to be particularly susceptible to this therapy.

l of 1 3/29/03 1:59 PM